Cargando…

Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy

Collagen, the most abundant protein in mammal, is widely expressed in tissues and organs, as well as tumor extracellular matrix. Tumor collagen mainly accumulates in tumor stroma or beneath tumor blood vessel endothelium, and is exposed due to the fragmentary structure of tumor blood vessels. Throug...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiayang, Pan, Danjie, Huang, Xuan, Wang, Songna, Chen, Huaning, Zhu, Yi Zhun, Ye, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484796/
https://www.ncbi.nlm.nih.gov/pubmed/37692860
http://dx.doi.org/10.3389/fonc.2023.1225483
_version_ 1785102662358794240
author Liu, Jiayang
Pan, Danjie
Huang, Xuan
Wang, Songna
Chen, Huaning
Zhu, Yi Zhun
Ye, Li
author_facet Liu, Jiayang
Pan, Danjie
Huang, Xuan
Wang, Songna
Chen, Huaning
Zhu, Yi Zhun
Ye, Li
author_sort Liu, Jiayang
collection PubMed
description Collagen, the most abundant protein in mammal, is widely expressed in tissues and organs, as well as tumor extracellular matrix. Tumor collagen mainly accumulates in tumor stroma or beneath tumor blood vessel endothelium, and is exposed due to the fragmentary structure of tumor blood vessels. Through the blood vessels with enhanced permeability and retention (EPR) effect, collagen-binding macromolecules could easily bind to tumor collagen and accumulate within tumor, supporting tumor collagen to be a potential tumor-specific target. Recently, numerous studies have verified that targeting collagen within tumor extracellular matrix (TEM) would enhance the accumulation and retention of immunotherapy drugs at tumor, significantly improving their anti-tumor efficacy, as well as avoiding severe adverse effects. In this review, we would summarize the known collagen-binding domains (CBD) or proteins (CBP), their mechanism and application in tumor-targeting immunotherapy, and look forward to future development.
format Online
Article
Text
id pubmed-10484796
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104847962023-09-09 Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy Liu, Jiayang Pan, Danjie Huang, Xuan Wang, Songna Chen, Huaning Zhu, Yi Zhun Ye, Li Front Oncol Oncology Collagen, the most abundant protein in mammal, is widely expressed in tissues and organs, as well as tumor extracellular matrix. Tumor collagen mainly accumulates in tumor stroma or beneath tumor blood vessel endothelium, and is exposed due to the fragmentary structure of tumor blood vessels. Through the blood vessels with enhanced permeability and retention (EPR) effect, collagen-binding macromolecules could easily bind to tumor collagen and accumulate within tumor, supporting tumor collagen to be a potential tumor-specific target. Recently, numerous studies have verified that targeting collagen within tumor extracellular matrix (TEM) would enhance the accumulation and retention of immunotherapy drugs at tumor, significantly improving their anti-tumor efficacy, as well as avoiding severe adverse effects. In this review, we would summarize the known collagen-binding domains (CBD) or proteins (CBP), their mechanism and application in tumor-targeting immunotherapy, and look forward to future development. Frontiers Media S.A. 2023-08-24 /pmc/articles/PMC10484796/ /pubmed/37692860 http://dx.doi.org/10.3389/fonc.2023.1225483 Text en Copyright © 2023 Liu, Pan, Huang, Wang, Chen, Zhu and Ye https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Jiayang
Pan, Danjie
Huang, Xuan
Wang, Songna
Chen, Huaning
Zhu, Yi Zhun
Ye, Li
Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title_full Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title_fullStr Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title_full_unstemmed Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title_short Targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
title_sort targeting collagen in tumor extracellular matrix as a novel targeted strategy in cancer immunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484796/
https://www.ncbi.nlm.nih.gov/pubmed/37692860
http://dx.doi.org/10.3389/fonc.2023.1225483
work_keys_str_mv AT liujiayang targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT pandanjie targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT huangxuan targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT wangsongna targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT chenhuaning targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT zhuyizhun targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy
AT yeli targetingcollagenintumorextracellularmatrixasanoveltargetedstrategyincancerimmunotherapy